Dr. Muhammad Ali Pervaiz, MD

Dr. Pervaiz practices at Wellstar North Fulton Medical Center in Roswell, Georgia, part of Wellstar Health System.

Dr. Pervaiz's NPI, 1417174186, was assigned on April 20, 2007. Dr. Pervaiz holds Georgia license 060549.

Dr. Pervaiz's primary practice is Wellstar North Fulton Medical Center, at 3000 Hospital Boulevard, Roswell, GA 30076 in Fulton County. The practice phone is (770) 751-2500.

Dr. Pervaiz's primary practice is Wellstar North Fulton Medical Center in Roswell, Georgia, part of Wellstar Health System. Dr. Pervaiz is also affiliated with Wellstar Kennestone Regional Medical Center. The medical group on file is Apogee Medical Group Georgia. Dmand AI also links Dr. Pervaiz to 4 more hospitals, 11 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pervaiz practices, 8 sites in all. Vendor and product names are available with a free account.

Hospitalist is Dr. Pervaiz's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Dmand AI has Dr. Pervaiz's licenses on file in 4 states: Georgia, Minnesota, New Hampshire and Wisconsin.

CMS data shows 328 Medicare services from Dr. Pervaiz across 4 procedure codes in 2024, for 300 Medicare patients. Medicare paid $38,582 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 300 Medicare patients who saw Dr. Pervaiz in 2024. The largest group is 75 to 84, with 109 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pervaiz's median patient age at 69, with 64% women.

In 2024, Dr. Pervaiz wrote 68 Medicare Part D claims for 20 patients. 78% of them were for generic drugs. CMS names the drug for 24 of them, across 2 drugs with 11 or more claims each, at $358,008 in total drug cost. In 2019, CMS named 63 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Pervaiz for performance year 2024, reported through an alternative payment model (APM).

Dmand AI links 4 papers to Dr. Pervaiz, published from 2011 to 2012. Dr. Pervaiz has published most often in Indian J Hum Genet. Dr. Pervaiz's most frequent co-authors are Serge Geffrard, MD and Allan S. Jaffe, MD.

CMS Open Payments shows 41 general payments to Dr. Pervaiz from 17 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 100% of the total. Otsuka America Pharmaceutical, Inc. paid the most, $130.